Germline BRCA1 and BRCA2 mutations have been associated with benefit from PARP inhibitors in pancreatic cancer, and inhibitor olaparib has been approved for maintenance treatment of metastatic pancreatic cancer patients with such mutations after non-progression to first-line platinum-based chemotherapy [12]. This evidence concerns the gene BRCA2 and pancreatic neoplasm.